Tumor, Solid Clinical Trial
Official title:
Exploratory Clinical Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors
The goal of this clinical trial is to learn if tumor neoantigen-specific T cells can treat patients with advanced solid tumors. The main questions it aims to answer are: Evaluate the safety of intravenous infusion of tumor neoantigen-specific T cells in the treatment of advanced solid tumors such as ovarian cancer, non-small cell lung cancer, and colorectal cancer. To evaluate the effectiveness of intravenous infusion of tumor neoantigen-specific T cells in the treatment of advanced solid tumors such as ovarian cancer, non-small cell lung cancer, and colorectal cancer and to study its immunological properties in patients.
In this open, single-armed study, selected patients with advanced solid tumor confirmed by Histopathology will be received tumor neoantigen specific T cells treatment. First, their tumor specimen will be collected from surgery or puncture，then their PBMC will be separated by blood cell separator. This cells will be cultured and selected in GMP laboratory to make tumor neoantigen specific T cells. The tumor neoantigen specific T cells will be infused intravenous into patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05637034 -
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
|
N/A | |
| Terminated |
NCT04095091 -
Real-time Tumor Localization and Guidance for Radiotherapy Using Ultrasound (US) and Magnetic Resonance (MR)
|
||
| Recruiting |
NCT05378425 -
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
|
Phase 1 | |
| Not yet recruiting |
NCT04723810 -
TumorGlow Intraoperative Molecular Imaging (IMI)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06116032 -
Immune Profiling for Cancer Immunotherapy Response
|
||
| Recruiting |
NCT06090266 -
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04416165 -
Comparison of FDG and FAPI in Patients With Various Types of Cancer
|
N/A | |
| Recruiting |
NCT05620134 -
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04750772 -
Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer
|
N/A | |
| Recruiting |
NCT06022029 -
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
|
Phase 1 | |
| Terminated |
NCT01358331 -
A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)
|
Phase 1 | |
| Recruiting |
NCT06175221 -
Autologous TLPO Vaccine Basket
|
Phase 2 | |
| Recruiting |
NCT05661461 -
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
|
Phase 1 | |
| Active, not recruiting |
NCT04196530 -
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab
|
Phase 1 | |
| Not yet recruiting |
NCT03731390 -
GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma
|
Phase 1 | |
| Active, not recruiting |
NCT03491631 -
Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06193902 -
LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04528836 -
First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05221320 -
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
|
Phase 2 |